Treatment of Schizoaffective Disorder
March 2009
by Elisa Cascade; Amir H. Kalali, MD; and Peter Buckley, MD
Ms. Cascade is Vice President, Quintiles Inc./iGuard, Falls Church, Virginia; Dr. Kalali is Vice President, Global Therapeutic Group Leader CNS, Quintiles Inc., San Diego, California, and Professor of Psychiatry, University of California, San Diego; and Dr. Buckley is Professor and Chairman, Department of Psychiatry, Medical College of Georgia, Augusta, Georgia.
This is protected content.
Popularity: unranked [?]
Related posts
- Generic Penetration in the Retail Antidepressant Market
- Extended-release Trazodone in Major Depressive Disorder: A Randomized, Double-blind, Placebo-controlled Study
- Real-World Data on SSRI Antidepressant Side Effects
- Use of Benzodiazepines in the Treatment of Anxiety
- Tramadol: Seizures, Serotonin Syndrome, and Coadministered Antidepressants
- Warfarin and Antidepressants: Happiness without Hemorrhaging
- Decreased Use of Antidepressants in Youth After US Food and Drug Administration Black Box Warning
- Antidepressant Prescribing by Specialty and Treatment of Premenstrual Dysphoric Disorder
- Treatment of Bipolar Disorder
Posted in Trend Watch | No Comments »
